EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study

Miloš Mitrović, Verica Stanković Popović, Sanja Erceg iD, Milena Perišić Mitrović, Ana Dobrosavljević, Andrej Stupar, Petra Vuković, Dušan Zlatković, Petar Svorcan

International Journal of Molecular Sciences · 10.06.2025 · 26 (12) · 5561

DOI: 10.3390/ijms26125561 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.06.2025. Verfasst von Miloš Mitrović und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, University Medical Center Zvezdara, 11080 Belgrade, Serbia. Hauptthemen laut MEDLINE: Butyric Acid, Dietary Supplements, Fatty Liver, Butyrates. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common cause of chronic liver disease and is closely associated with metabolic abnormalities and cardiovascular risks. Butyrate, a short-chain fatty acid produced by gut microbiota, has the potential to enhance liver health by modulating inflammation and supporting gut barrier integrity. This study aimed to investigate and compare the effects of sodium butyrate and calcium butyrate in patients with MASLD. In this single-center, randomized clinical trial, 181 patients with MASLD were enrolled and assigned to receive either sodium butyrate (n = 121) or calcium butyrate (n = 60) supplementation at a daily dose of 1000 mg. The primary endpoint was the change in liver steatosis, measured using the Controlled Attenuation Parameter (CAP) via FibroScan®. Secondary endpoints included liver stiffness, biochemical parameters, hepatic steatosis and fatty liver indices, fecal calprotectin levels, stool short-chain fatty acid levels, and microbiome composition. A subgroup analysis compared responders (a ≥ 5% reduction in CAP) to non-responders. There were no significant changes in CAP values for either group (ΔCAP: sodium butyrate, 0.84; calcium butyrate, −0.23; p = 0.70). Sodium butyrate significantly reduced serum trimethylamine N-oxide and fatty liver index, while calcium butyrate led to a decrease in fecal calprotectin levels. Responders demonstrated a lower body mass index, higher levels of high-sensitivity C-reactive protein and HbA1c, and distinct microbiome profiles, characterized by lower abundance of Subdoligranulum and higher abundance of Catenibacterium. Although butyrate supplementation did not significantly improve liver steatosis as measured by CAP, the differing effects on metabolic and inflammatory markers suggest that there may be potential benefits for specific subgroups of patients with MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Butyric AcidDietary SupplementsFatty LiverButyratesHumansMaleFemaleMiddle AgedGastrointestinal MicrobiomeAgedAdultAdministration, OralLiverFatty Acids, Volatile

Stichwörter der Autor:innen

butyrate supplementationinflammationmetabolic dysfunction-associated steatotic liver diseasemicrobiome

Substanzen

Butyric AcidButyratesFatty Acids, Volatile

Autor:innen und Institutionen

  • Department of Gastroenterology, University Medical Center Zvezdara, 11080 Belgrade, Serbia.
  • School of Medicine, Belgrade University, 11080 Belgrade, Serbia.
  • Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade University, 11080 Belgrade, Serbia.

ORCID-Profile: Sanja Erceg

Zitieren

APA

Mitrović, M., Stanković Popović, V., Erceg, S., Perišić Mitrović, M., Dobrosavljević, A., Stupar, A., Vuković, P., Zlatković, D., & Svorcan, P. (2025). Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study. International Journal of Molecular Sciences, 26(12), 5561. https://doi.org/10.3390/ijms26125561

Vancouver

Mitrović M, Stanković Popović V, Erceg S, Perišić Mitrović M, Dobrosavljević A, Stupar A, et al. Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study. International Journal of Molecular Sciences. 2025;26(12):5561. doi:10.3390/ijms26125561

BibTeX
@article{Mitrovi2025,
  author = {Mitrović, Miloš and Stanković Popović, Verica and Erceg, Sanja and Perišić Mitrović, Milena and Dobrosavljević, Ana and Stupar, Andrej and Vuković, Petra and Zlatković, Dušan and Svorcan, Petar},
  title = {Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {12},
  pages = {5561},
  doi = {10.3390/ijms26125561}
}
Kostenlos starten →